Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Lynce, Filipa ¹     ; Mainor, Candace ²     ; Donahue, Renee N. ³     ; Geng, Xue ⁴     ; Jones, Greg ⁵     ; Schlam, Ilana ⁶     ; Wang, Hongkun ⁴ ; Toney, Nicole J. ³ ; Jochems, Caroline ³     ; Schlom, Jeffrey ³     ; Zeck, Jay ²     ; Gallagher, Christopher ⁷     ; Nanda, Rita ⁸     ; Graham, Deena ⁹     ; Stringer-Reasor, Erica M. ¹⁰ ; Denduluri, Neelima ¹¹     ; Collins, Julie ¹²     ; Chitalia, Ami ⁷     ; Tiwari, Shruti ⁷ ; Nunes, Raquel ¹³     ; Kaltman, Rebecca ¹⁴ ; Khoury, Katia ¹⁰     ; Gatti-Mays, Margaret ¹⁵ ; Tarantino, Paolo ¹⁶     ; Tolaney, Sara M. ¹     ; Swain, Sandra M. ⁴     ; Pohlmann, Paula ² ; Parsons, Heather A. ¹     ; Isaacs, Claudine <sup>4    

1</sup>  Dana-Farber Cancer Institute, Division of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
²  MedStar Georgetown University Hospital, Washington, USA (GRID:grid.411663.7) (ISNI:0000 0000 8937 0972) 
³  Center for Cancer Research, National Cancer Institute, National Institutes of Health, Center for Immuno-Oncology, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
⁴  Georgetown University, Washington, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644) 
⁵  NeoGenomics, Durham, USA (GRID:grid.504533.4) (ISNI:0000 0004 6021 2021) 
⁶  MedStar Washington Hospital Center, Washington, USA (GRID:grid.415235.4) (ISNI:0000 0000 8585 5745); Tufts Medical Center, Boston, USA (GRID:grid.67033.31) (ISNI:0000 0000 8934 4045) 
⁷  MedStar Washington Hospital Center, Washington, USA (GRID:grid.415235.4) (ISNI:0000 0000 8585 5745) 
⁸  University of Chicago, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822) 
⁹  Hackensack University Medical Center, Hackensack, USA (GRID:grid.239835.6) (ISNI:0000 0004 0407 6328) 
¹⁰  University of Alabama at Birmingham, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000 0001 0634 4187) 
¹¹  AstraZeneca, Arlington, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493) 
¹²  MedStar Georgetown University Hospital, Washington, USA (GRID:grid.411663.7) (ISNI:0000 0000 8937 0972); AstraZeneca, Arlington, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493) 
¹³  Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625); AstraZeneca, Arlington, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493) 
¹⁴  Inova, Fairfax, USA (GRID:grid.418152.b) 
¹⁵  The Ohio State University, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943) 
¹⁶  Dana-Farber Cancer Institute, Division of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)